Michael Krebs

HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation.

HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation.

Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996.

Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996.

Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996.

HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation.